BOSTON, Oct. 14 /PRNewswire/ -- Surface Logix, a privately held biopharmaceutical company focused on using biophysical chemistry to create and develop novel small molecule drugs, is pleased to announce the appointment of Keith Dionne, Ph.D. to the position of President and Chief Executive Officer and to its Board of Directors. Dr. Dionne is a seasoned executive with nearly 20 years of leadership experience in the biotechnology industry.
"We are delighted to welcome Keith at this important stage of Surface Logix's development," stated Steven Gillis, Ph.D., Managing Director at ARCH Venture Partners and Chairman of Surface Logix. "We are confident that his proven track record and depth of experience will be instrumental as the Company continues to make progress on a number of fronts, including the further clinical development of two candidates in Phase 2 clinical trials."
Dr. Dionne was previously CEO of Alantos Pharmaceuticals, where he led the Company through a successful acquisition by Amgen for more than $300 million in cash. Prior to Alantos, Dr. Dionne held senior-level positions at Millennium Pharmaceuticals, including most recently Vice President of Research and Development Strategy and Vice President & General Manager: Technology Business. Before his 7-year tenure at Millennium, Dr. Dionne provided scientific leadership at ALZA Pharmaceuticals as Head of Pre-Clinical Research & Development: Implants.
"Surface Logix appealed to me because of its mature, differentiated pipeline, its exciting discovery capabilities and the strong team of discovery and development professionals," said Dr. Dionne. "I look forward to working with this team and our experienced Board and investors to fully realize the value of Surface Logix's late stage clinical assets and our discovery engine."
Dr. Dionne earned both his Ph.D. in Chemical Engineering and his M.S.
in the Program for Technology Policy from the Massachusetts Institute of
|SOURCE Surface Logix Inc.|
Copyright©2008 PR Newswire.
All rights reserved